- Home
- LXFR vs PRTA Comparison
LXFR vs PRTA Comparison
Compare LXFR & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXFR
- PRTA
- Stock Information
- Founded
- LXFR 1898
- PRTA 2012
- Country
- LXFR United States
- PRTA Ireland
- Employees
- LXFR N/A
- PRTA N/A
- Industry
- LXFR Major Chemicals
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- LXFR Industrials
- PRTA Health Care
- Exchange
- LXFR Nasdaq
- PRTA Nasdaq
- Market Cap
- LXFR 331.9M
- PRTA 366.6M
- IPO Year
- LXFR 2012
- PRTA N/A
- Fundamental
- Price
- LXFR $12.45
- PRTA $8.52
- Analyst Decision
- LXFR
- PRTA Buy
- Analyst Count
- LXFR 0
- PRTA 10
- Target Price
- LXFR N/A
- PRTA $24.29
- AVG Volume (30 Days)
- LXFR 129.1K
- PRTA 1.1M
- Earning Date
- LXFR 07-29-2025
- PRTA 08-04-2025
- Dividend Yield
- LXFR 4.15%
- PRTA N/A
- EPS Growth
- LXFR N/A
- PRTA N/A
- EPS
- LXFR 0.90
- PRTA N/A
- Revenue
- LXFR $403,800,000.00
- PRTA $10,341,000.00
- Revenue This Year
- LXFR $2.63
- PRTA N/A
- Revenue Next Year
- LXFR $3.30
- PRTA $122.46
- P/E Ratio
- LXFR $12.83
- PRTA N/A
- Revenue Growth
- LXFR 5.60
- PRTA N/A
- 52 Week Low
- LXFR $9.41
- PRTA $4.32
- 52 Week High
- LXFR $15.64
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- LXFR 54.41
- PRTA 77.59
- Support Level
- LXFR $12.36
- PRTA $7.39
- Resistance Level
- LXFR $12.68
- PRTA $8.70
- Average True Range (ATR)
- LXFR 0.38
- PRTA 0.43
- MACD
- LXFR 0.04
- PRTA 0.10
- Stochastic Oscillator
- LXFR 70.00
- PRTA 91.39
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.